SANTA CLARA, Calif.--(BUSINESS WIRE)--XenoPort, Inc. (Nasdaq:XNPT) today announced results of a placebo-controlled, dose-escalating, repeat-dose Phase 1 clinical trial of XP19986 formulated in a sustained-release tablet, designated as SR3. The trial demonstrated sustained levels of XP19986 over 24 hours and enabled identification of suitable doses for further clinical studies of XP19986. XenoPort plans to initiate a Phase 2 clinical trial of the XP19986 SR3 formulation in gastroesophageal reflux disease (GERD) patients later this year. In addition, XenoPort plans to initiate later this year a Phase 2 clinical trial in patients with spasticity that will be conducted with a second formulation of XP19986, designated as SR1.
